This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (17)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal

Arch Ophthalmol. 2002;120:829-830.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

THE TREATMENT of ocular hypertension has been problematical in the few decades since it was recognized by Chandler¹ and Armaly² that only a minority of such patients were destined to develop glaucomatous damage.

On the conservative side, many glaucoma specialists advocate following such patients without treatment unless the intraocular pressure (IOP) is quite high (eg, 30 mm Hg)³ or if it is difficult to be sure that the optic disc and visual field are normal. It is reasoned that observation alone allows timely intervention if damage begins, long before visual loss of consequence to the patient would occur, that in this way as many as 80% of patients with ocular hypertension avoid the cost and adverse effects of therapy, and that there is actually no convincing evidence that treatment delays or prevents damage.

On the other side of the debate, it is argued that up to 20% to 50% of . . . [Full Text of this Article]

RELATED ARTICLES

The Ocular Hypertension Treatment Study: A Randomized Trial Determines That Topical Ocular Hypotensive Medication Delays or Prevents the Onset of Primary Open-Angle Glaucoma
Michael A. Kass, Dale K. Heuer, Eve J. Higginbotham, Chris A. Johnson, John L. Keltner, J. Philip Miller, Richard K. Parrish II, M. Roy Wilson, Mae O. Gordon, and for the Ocular Hypertension Treatment Study Group
Arch Ophthalmol. 2002;120(6):701-713.
ABSTRACT | FULL TEXT  

The Ocular Hypertension Treatment Study: Baseline Factors That Predict the Onset of Primary Open-Angle Glaucoma
Mae O. Gordon, Julia A. Beiser, James D. Brandt, Dale K. Heuer, Eve J. Higginbotham, Chris A. Johnson, John L. Keltner, J. Philip Miller, Richard K. Parrish II, M. Roy Wilson, Michael A. Kass, and for the Ocular Hypertension Treatment Study Group
Arch Ophthalmol. 2002;120(6):714-720.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Central corneal thickness and its relationship to myopia in Chinese adults
Fam et al.
Br. J. Ophthalmol. 2006;90:1451-1453.
ABSTRACT | FULL TEXT  

The quality of reporting of diagnostic accuracy studies in glaucoma using the heidelberg retina tomograph.
Shunmugam and Azuara-Blanco
IOVS 2006;47:2317-2323.
ABSTRACT | FULL TEXT  

Clinical Significance of Central Corneal Thickness in the Management of Glaucoma
Shih et al.
Arch Ophthalmol 2004;122:1270-1275.
ABSTRACT | FULL TEXT  

We Should Treat Fewer Patients With Elevated Intraocular Pressure Now That We Know the Results of the Ocular Hypertension Treatment Study
Jampel
Arch Ophthalmol 2004;122:378-379.
FULL TEXT  

Expectations From Clinical Trials: Results of the Early Manifest Glaucoma Trial
Lichter
Arch Ophthalmol 2002;120:1371-1372.
FULL TEXT  

Does Treatment of Elevated Intraocular Pressure Prevent Glaucoma?
Journal Watch Dermatology 2002;2002:13-13.
FULL TEXT  

Does Treatment of Elevated Intraocular Pressure Prevent Glaucoma?
JWatch General 2002;2002:1-1.
FULL TEXT